{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:54:12Z","timestamp":1772171652106,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.phrs.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T12:46:23Z","timestamp":1536583583000},"page":"270-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort"],"prefix":"10.1016","volume":"137","author":[{"given":"Marco","family":"Mirani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Favacchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliseo","family":"Serone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lucisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare C.","family":"Berra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.09.003_bib0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Study GBD","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.09.003_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2018.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2018.09.003_bib0025","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. Diabetes care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00592-014-0688-6","article-title":"Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative","volume":"52","author":"Rossi","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2018.09.003_bib0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1463-1326.2012.01591.x","article-title":"Glucose-lowering treatment and clinical results in 163121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register","volume":"14","author":"Ekstr\u00f6m","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2018.09.003_bib0040","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2018.09.003_bib0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13135","article-title":"A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials","volume":"20","author":"Deacon","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"February (Suppl 1)","key":"10.1016\/j.phrs.2018.09.003_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2018.09.003_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.diabres.2017.11.023","article-title":"SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type 2 diabetes mellitus","volume":"136","author":"d\u2019Emden","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2018.09.003_bib0060","series-title":"U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Diabetes Mellitus\u2014evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","year":"2008"},{"key":"10.1016\/j.phrs.2018.09.003_bib0065","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.numecd.2016.05.007","article-title":"Novel antidiabetic drugs and cardiovascular risk: primum non nocere","volume":"26","author":"Bonadonna","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"111","key":"10.1016\/j.phrs.2018.09.003_bib0070","article-title":"Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice","volume":"15","author":"Avogaro","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.phrs.2018.09.003_bib0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17512433.2017.1287562","article-title":"SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs","volume":"10","author":"Singh","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.09.003_bib0080","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"586","key":"10.1016\/j.phrs.2018.09.003_bib0090","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0095","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"3","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0100","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0110","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0115","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0120","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.003_bib0125","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2018.09.003_bib0130","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00125-016-3987-3","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2018.09.003_bib0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/dom.13178","article-title":"What have we learnt from \"real world\" data, observational studies and meta-analyses","volume":"20","author":"Chatterjee","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2018.09.003_bib0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","article-title":"Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review","volume":"7","author":"Ostawal","year":"2016","journal-title":"Diabetes Ther."},{"issue":"December","key":"10.1016\/j.phrs.2018.09.003_bib0145","article-title":"Long-term effectiveness of liraglutide for treatment of type 2 diabetes in a real-life setting: a 24-month, multicenter, non-interventional, retrospective study","author":"Lapolla","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2018.09.003_bib0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clinthera.2016.11.001","article-title":"Use of liraglutide in the real world and impact at 36 months on metabolic control, weight, lipid profile, blood pressure, heart rate, and renal function","volume":"39","author":"Rondinelli","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2018.09.003_bib0155","first-page":"35","article-title":"Effectiveness and safety of liraglutide after three years of treatment","volume":"41","author":"Ponzani","year":"2016","journal-title":"Minerva Endocrinol."},{"issue":"December","key":"10.1016\/j.phrs.2018.09.003_bib0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2017.07.081","article-title":"Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes","volume":"248","author":"Engelen","year":"2017","journal-title":"Int. J. Cardiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181830882X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181830882X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:57:44Z","timestamp":1760911064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181830882X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"alternative-id":["S104366181830882X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.09.003","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}